The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Open accessAbstract
Androgen receptor (AR) splice variants lacking the ligand binding domain (ARVs), originally isolated from prostate cancer cell lines derived from a single patient, are detected in normal and malignant human prostate tissue, with the highest levels observed in late stage, castration-resistant prostate cancer. The most studied variant (called AR-V7 or AR3) activates AR reporter genes in the absence of ligand and therefore, could play a role in castration resistance. To explore the range of potential ARVs, we screened additional human and murine prostate cancer models using conventional and next generation sequencing technologies and detected several structurally diverse AR isoforms. Some, like AR-V7/AR3, display gain of function, whereas others have dominant interfering activity. We also find that ARV expression increases acutely in response to androgen withdrawal, is suppressed by testosterone, and in some models, is coupled to full-length AR (AR-FL) mRNA production. As expected, constitutively active, ligand-independent ARVs such as AR-V7/AR3 are sufficient to confer anchorage-independent (in vitro) and castration-resistant (in vivo) growth. Surprisingly, this growth is blocked by ligand binding domain-targeted antiandrogens, such as MDV3100, or by selective siRNA silencing of AR-FL, indicating that the growth-promoting effects of ARVs are mediated through AR-FL. These data indicate that the increase in ARV expression in castrate-resistant prostate cancer is an acute response to castration rather than clonal expansion of castration or antiandrogen-resistant cells expressing gain of function ARVs, and furthermore, they provide a strategy to overcome ARV function in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of these variants still depends on the presence of a full-length AR, although treatment with the AR antagonist MDV3100 or siRNA knockdown of full-length AR inhibited transcription and androgen-free growth (77).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [77]
In the citing paper
“Moreover, the constitutive activity attributed to some variants may still rely on the presence of the full-length AR to mediate binding of AR to DNA and stimulate transcription (77).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [77]
In the citing paper
“In one study, endogenous expression of variant mRNA in patient samples and xenografts is much lower (ϳ0.1-2.5%)relative to full-length AR mRNA (77).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [77]
In the citing paper
“Interestingly, comparison of the transcriptome of variants with that of full-length AR suggests a significant amount of target specificity for each variant (76 -78).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [77]
In the citing paper
“Two such variants, human AR-V7, identified in CR prostate cancer specimens, and mouse AR-V4, from the murine Myc-CaP cell line, demonstrate ligand-free activation of a 4xARE-Luc promoter as well as promoting CR LNCaP tumor growth.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,682
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Self-citationHu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M., Efstathiou, E., Rathkopf, D. E., Shelkey, J., Yu, E. Y., Alumkal, J. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citationGuo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
He, B., Kemppainen, J., & Wilson, E. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002807200 · Cited by 441
Molecular basis of androgen insensitivity
Brinkmann, A. O. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00466-x · Cited by 345
Cited by
Sorted by citations
Items 401–500 of 643
Raddeanin A down‐regulates androgen receptor and its splice variants in prostate cancer
Xia, H., Hu, C., Bai, S., Lyu, J., Zhang, B. Y., Yu, X., Zhan, Y., Zhao, L., & Dong, Y. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14267 · Cited by 13
Chou, F.-J., Lin, C.-Y., Tian, H., Lin, W.-Y., You, B., Lu, J., Sahasrabudhe, D. M., Huang, C., Yang, V., Yeh, S., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02970-4 · Cited by 14
Luo, J., & Pienta, K. J. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.012 · Cited by 14
Halabi, S., Guo, S., Park, J. J., Nanus, D. M., George, D. J., Antonarakis, E. S., Danila, D. C., Szmulewitz, R. Z., McDonnell, D. P., Norris, J. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3017 · Cited by 13
Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
Srivastava, T. P., Dhar, R., & Karmakar, S. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-024-01338-z · Cited by 13
Chi, K. N., McKay, R. R., Sandhu, S. K., Arranz, J. Á., Barthélémy, P., Hadaschik, B. A., Matsubara, N., Shore, N. D., Ye, D., Cascella, T., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2502318 · Cited by 14
Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou, V., Notas, G., Stathopoulos, E. N., Castanas, E., & Kampa, M. (2013) · HORMONES · doi:10.14310/horm.2002.1406 · Cited by 14
Knuuttila, M., Mehmood, A., Huhtaniemi, R., Yatkin, E., Häkkinen, M. R., Oksala, R., Laajala, T. D., Ryberg, H., Handelsman, D. J., Aittokallio, T. A., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.08.036 · Cited by 15
Han, D. G., Gao, S., Valencia, K., Owiredu, J. N., Han, W., de Waal, E., Macoska, J. A., & Cai, C. (2016) · Oncotarget · doi:10.18632/oncotarget.14296 · Cited by 13
Jinna, N., Rida, P. C. G., Smart, M., LaBarge, M. A., Jovanović‐Talisman, T., Natarajan, R. D., & Seewaldt, V. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168844 · Cited by 13
Allosteric alterations in the androgen receptor and activity in prostate cancer
Uo, T., Plymate, S. R., & Sprenger, C. C. T. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0108 · Cited by 15
Khan, T., Scott, K. F., Becker, T. M., Lock, J. G., Nimir, M., Ma, Y., & SOUZA, P. D. (2020) · Prostate Cancer · doi:10.1155/2020/7938280 · Cited by 13
The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells
Xu, J., Yang, X., Deshmukh, D., Chen, H., Fang, S., & Qiu, Y. (2020) · Cells · doi:10.3390/cells9051094 · Cited by 13
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
Rosario, D. J., Greasley, R., & Khabazhaitajer, M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s50585 · Cited by 13
Li, Y., Chu, Y., Shi, G., Wang, X., Ye, W., Shan, C., Wang, D., Zhang, D., He, W., Jiang, J., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.003 · Cited by 12
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives
Leone, G., Buttigliero, C., Pisano, C., Stefano, R. F. D., Tabbò, F., Turco, F., Vignani, F., Scagliotti, G. V., Maïo, M. D., & Tucci, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102994 · Cited by 12
DNA binding alters ARv7 dimer interactions
Özgün, F., Kaya, Z., Morova, T., Geverts, B., Abraham, T. E., Houtsmuller, A. B., van Royen, M. E., & Lack, N. A. (2021) · Journal of Cell Science · doi:10.1242/jcs.258332 · Cited by 12
Application of fluorine-containing non-steroidal anti-androgen compounds in treating prostate cancer
Yang, X., & Guan, A. (2014) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2014.02.001 · Cited by 12
Overview on the complexity of androgen receptor-targeted therapy for prostate cancer
Farooqı, A. A., & Sarkar, F. H. (2015) · Cancer Cell International · doi:10.1186/s12935-014-0153-1 · Cited by 12
Daniel, M. L., & Dehm, S. M. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.016 · Cited by 12
Reddy, V., Iskander, A., Hwang, C., Divine, G., Menon, M., Barrack, E. R., Reddy, G. P., & Kim, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211090 · Cited by 12
New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer
Godbole, A. M., & Njar, V. C. O. (2011) · Prostate Cancer · doi:10.1155/2011/918707 · Cited by 12
MicroRNAs in androgen-dependent PCa
Sun, J. (2012) · Frontiers in bioscience · doi:10.2741/4137 · Cited by 12
Use of PARP inhibitors in prostate cancer: from specific to broader application
Zhang, Z., Diao, L., Zhang, C., Wang, F., Guan, X., & Yao, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1164067 · Cited by 12
Buck, S. A. J., Hemelryk, A. V., de Ridder, C., Stuurman, D. C., Erkens‐Schulze, S., Geloof, S. V. ’., Teubel, W. J., Koolen, S. L. W., Martens‐Uzunova, E. S., van Royen, M. E., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0420 · Cited by 11
UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer
Lee, S., Kim, H.-R., Woo, Y., Kim, J., Kim, H. W., Park, J. Y., Suh, B., Choi, Y.-R., Ahn, J., Ryu, J. H., et al. (2024) · Advanced Science · doi:10.1002/advs.202400398 · Cited by 12
Development of enzalutamide for metastatic castration‐resistant prostate cancer
Bhattacharya, S., Hirmand, M., Phung, D., & van Os, S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12846 · Cited by 11
Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer
Pal, S. K., & Sartor, O. A. (2011) · Asian Journal of Andrology · doi:10.1038/aja.2011.35 · Cited by 11
Mechanisms and targeting of proteosome-dependent androgen receptor degradation in prostate cancer.
Fang, Q., Cole, R. N., & Wang, Z. (2022) · PubMed Central · Cited by 11
Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine
Guo, Z., ZHANG, X., Li, X., Xie, F., Su, B., Zhang, M., & Zhou, L. (2014) · Oncology Reports · doi:10.3892/or.2014.3696 · Cited by 11
Alanazi, I. O., Shehri, Z. S. A., Ebrahimie, E., Giahi, H., & Dehcheshmeh, M. M. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.22975 · Cited by 11
Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival
Giordano, F., Naimo, G. D., Nigro, A., Romeo, F., Paolì, A., Amicis, F. D., Vivacqua, A., Morelli, C., Mauro, L., & Panno, M. L. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s229930 · Cited by 11
Zhang, M., Lai, Y., Vasquez, J. L., James, D. I., Smith, K. M., Waddell, I. D., Ogilvie, D., Liu, Y., & Agoulnik, I. U. (2020) · Scientific Reports · doi:10.1038/s41598-020-60849-y · Cited by 11
Case, T. C., Merkel, A. R., Ramirez-Solano, M. A., Liu, Q., Sterling, J. A. R., & Jin, R. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101213 · Cited by 11
Siciliano, T., Sommer, U. J., Beier, A.-M. K., Stope, M. B., Borkowetz, A., Thomas, C., & Erb, H. H. H. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44020041 · Cited by 12
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Slootbeek, P. H. J., Tolmeijer, S. H., Mehra, N., & Schalken, J. A. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2266482 · Cited by 12
IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor
Carter, S. L., Centenera, M. M., Tilley, W. D., Selth, L. A., & Butler, L. M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2188-2 · Cited by 10
Huhtaniemi, R., Sipilä, P., Junnila, A., Oksala, R., Knuuttila, M., Mehmood, A., Aho, E., Laajala, T. D., Aittokallio, T. A., Laiho, A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104287 · Cited by 13
Pak, S., Suh, J., Park, S. Y., Kim, Y., Cho, Y. M., & Ahn, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.972572 · Cited by 10
Chandrasekaran, B., Tyagi, A., Saran, U., Kolluru, V., Baby, B. V., Chirasani, V. R., Dokholyan, N. V., Lin, J.-M., Singh, A., Sharma, A. K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1137783 · Cited by 10
Yazan, L. S., Rahman, N. A., Chan, K. W., Hafiza, W. A. G. W. N., Tor, Y. S., & Foo, J. B. (2016) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2016.03.007 · Cited by 10
Shim, M., Kim, Y., Park, Y., & Ahn, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-53280-5 · Cited by 10
Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
Sartor, O. A., & Dong, Y. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.145069 · Cited by 11
Resistance to Hormonal Therapy in Prostate Cancer
Berruti, A., & Volta, A. D. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_21 · Cited by 11
Novel hormonal therapy for castration-resistant prostate cancer
Sternberg, C. N. (2012) · Annals of Oncology · doi:10.1093/annonc/mds362 · Cited by 10
Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer
Martin‐Caraballo, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084171 · Cited by 9
Epitranscriptomic mechanisms of androgen signalling and prostate cancer
Patke, R., Harris, A. E., Woodcock, C. L., Thompson, R., Santos, R. M., Kumari, A. A., Allegrucci, C., Archer, N., Gudas, L. J., Robinson, B. D., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101032 · Cited by 10
Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer
Hantusch, B., Kenner, L., Stanulović, V. S., Hoogenkamp, M., & Brown, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179245 · Cited by 10
Liang, M., Adisetiyo, H., Liu, X., Liu, R., Gill, P. S., Roy‐Burman, P., Jones, J. O., & Mulholland, D. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131232 · Cited by 10
Elgehama, A. M., Sun, L., Yu, B., Guo, W., & Xu, Q. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01050-w · Cited by 9
Jindal, R., Nanda, A., Pillai, M., Ware, K. E., Singh, D., Sehgal, M., Armstrong, A. J., Somarelli, J. A., & Jolly, M. K. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.031 · Cited by 8
Enzalutamide: looking back at its preclinical discovery
Ha, Y., & Kim, I. Y. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.918947 · Cited by 9
Xenograft, Transgenic, and Knockout Models of Prostate Cancer
Gaupel, A., Wang, W. W., Mordan‐McCombs, S., Lee, E. C. Y., & Tenniswood, M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00039-7 · Cited by 9
Ishii, H., Hattori, Y., Munetomo, A., Watanabe, H., Sakuma, Y., & Ozawa, H. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.04.009 · Cited by 9
Cottard, F., Madi-Berthélémy, P. O., Erdmann, É., Schaff-Wendling, F., Keime, C., Ye, T., Kurtz, J., & Céraline, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18270 · Cited by 10
Guo, J., Hu, J., Cao, R., Chen, Q., & Li, K. (2018) · Medical Science Monitor · doi:10.12659/msm.906836 · Cited by 9
Re, M. D., Crucitta, S., Restante, G., Rofi, E., Arrigoni, E., Biasco, E., Sbrana, A., Coppi, E., Galli, L., Sergio Bracarda, A., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.002 · Cited by 9
Hu, D. G., McKinnon, R. A., Hulin, J.-A., Mackenzie, P. I., & Meech, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010040 · Cited by 9
Schrader, A. J., Schrader, M. G., & Cronauer, M. V. (2013) · European Urology · doi:10.1016/j.eururo.2013.04.024 · Cited by 9
Schweizer, M. T., & Plymate, S. R. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1159676 · Cited by 9
Seo, E., Jee, B., Chung, J. H., Song, W., Sung, H. H., Jeon, H. G., Jeong, B. C., Seo, S. I., Jeon, S. S., Lee, H. M., et al. (2022) · FEBS Journal · doi:10.1111/febs.16657 · Cited by 8
BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients
Sugawara, T., Lejeune, P., Koehr, S., Neuhaus, R., Faus, H., Gelato, K. A., Busemann, M., Cleve, A., Lücking, U., von Nussbaum, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6864 · Cited by 8
Treatment of Castration-Resistant Prostate Cancer
Antonarakis, E. S., Carducci, M. A., & Eisenberger, M. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00110-9 · Cited by 9
Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer
Liu, J., Zhang, Y., Li, S., Sun, F., Wang, G., Dong, W., Yang, T., & Gu, S. (2021) · Oncology Reports · doi:10.3892/or.2021.8214 · Cited by 8
Molecular genetic mechanisms of drug resistance in prostate cancer
Krasnov, G. S., Dmitriev, A. A., Садритдинова, А. Ф., Волченко, Н. Н., Slavnova, E. N., Данилова, Т. В., Snezhkina, A. V., Melnikova, N. V., Fedorova, M., Lakunina, V. A., et al. (2015) · Molecular Biology · doi:10.1134/s0026893315050118 · Cited by 8
Experimental models for the development of new medical treatments in prostate cancer
Chauchereau, A. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70166-6 · Cited by 9
Effah, W., Khalil, M., Hwang, D., Miller, D. D., & Narayanan, R. (2024) · Steroids · doi:10.1016/j.steroids.2024.109486 · Cited by 9
AR Structural Variants and Prostate Cancer
Cato, L., & Shomali, M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_11 · Cited by 8
Modena, A., Ciccarese, C., Fantinel, E., Bimbatti, D., Tortora, G., & Massari, F. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1063423 · Cited by 7
Recepteur d'origine nantais (RON), more than a kinase: Role in castrate‐resistant prostate cancer
Batth, I. S., Yun, H., & Kumar, A. P. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22354 · Cited by 7
Krasnov, G. S., Dmitriev, A. A., Садритдинова, А. Ф., Волченко, Н. Н., Slavnova, E. N., Данилова, Т. В., Snezhkina, A. V., Melnikova, N. V., Fedorova, M., Lakunina, V. A., et al. (2015) · Molecular Biology · doi:10.7868/s0026898415050110 · Cited by 8
How splicing confers treatment resistance in prostate cancer
Konda, P., & Viswanathan, S. R. (2022) · eLife · doi:10.7554/elife.82070 · Cited by 7
Tyagi, A., Chandrasekaran, B., Shukla, V., Tyagi, N., Sharma, A. K., & Damodaran, C. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108743 · Cited by 6
Immune modulation by sex hormones: unveiling the complex interplay and regulatory networks
Wan, B., Chen, W., Shan, M., & Chi, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1748097 · Cited by 6
Alifrangis, C., Brown, C. O., Tuthill, M. H., & Waxman, J. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10570.x · Cited by 6
Luo, M., Zhang, Y., Xu, Z., Wu, C., Ye, Y., Liu, R., Lv, S., & Wei, Q. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01257-1 · Cited by 6
Chang, K., Chen, S., Sung, H., Hsu, S.-Y., Lin, W.-Y., Hou, C., Lin, Y., Feng, T., Tsui, K.-H., & Juang, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076245 · Cited by 6
Bhole, R. P., Karche, P. M., Gurav, S. S., & Chikhale, R. V. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101143 · Cited by 7
Mostaghel, E. A., Morgan, A. J., Zhang, X., Marck, B. T., Xia, J., Hunter‐Merrill, R. A., Gulati, R., Plymate, S. R., Vessella, R. L., Corey, E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111545 · Cited by 6
Garcı́a, J. L., Lozano, R., Misiewicz-Krzemińska, I., Fernández-Mateos, J., Krzemiński, P., Alfonso, S., Marcos, R. A., García, R., Gómez-Veiga, F., Virseda, A., et al. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1675-5 · Cited by 6
Role of the Androgen Receptor in Gender-Related Cancers
Sabbatino, E., Tutino, V., Licitra, F., Donato, M. D., Castoria, G., Migliaccio, A., & Giovannelli, P. (2023) · Endocrines · doi:10.3390/endocrines4020031 · Cited by 5
Lawrence, M. G., Keerthikumar, S., Townley, S. L., Clark, A. K., Cuffe, G. B., Laven‐Law, G., Hanson, A. R., Shrestha, R. K., Knutson, T. P., Richards, M. G., et al. (2025) · European Urology Focus · doi:10.1016/j.euf.2025.03.017 · Cited by 5
Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
Antonarakis, E. S., & Maughan, B. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.137680 · Cited by 5
Modi, P. K., Faiena, I., & Kim, I. Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00003-7 · Cited by 5
Plymate, S. R., & Luo, J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6182-1_13 · Cited by 5
Molecular Mechanisms of Noncoding RNA in the Occurrence of Castration-Resistant Prostate Cancer
Lin, Y., Tan, H., Yu, G., Zhan, M., & Xu, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021305 · Cited by 6
Proffitt, M. R., Liu, X., Ortlund, E. A., & Smith, G. T. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.112068 · Cited by 5
Computational analysis of treatment resistant cancer cells
Matov, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1723251 · Cited by 5
Velasco, M. A. D., Kura, Y., Ando, N., Sako, N., Banno, E., Fujita, K., Nozawa, M., Yoshimura, K., Sakai, K., Yoshikawa, K., et al. (2021) · Cancers · doi:10.3390/cancers13163975 · Cited by 5
Bahmad, H. F., Elhammady, G., Gass, J. M., Paramo, J. C., Poppiti, R., & Alexis, J. B. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45020061 · Cited by 5
Patki, M., Huang, Y., & Ratnam, M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.05.058 · Cited by 5
Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer
Hong, J. H. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1440288 · Cited by 5
Ebron, J. S., & Shukla, G. C. (2016) · The Prostate · doi:10.1002/pros.23174 · Cited by 5
Forootan, S. S., Hussain, S. A., Aachi, V., Foster, C. S., & Ke, Y. (2014) · Journal of Andrology and Gynaecology · doi:10.13188/2332-3442.1000017 · Cited by 5
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer
Virtanen, T., Kwan, E. M., Parekh, K., Bacon, J. V. W., Huang, C.-C. F., Yu, I. P. L., Ryyppö, L., Bernales, C. Q., Donnellan, G., Tam, C. S. L., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.1236 · Cited by 5
Androgen receptor post-translational modifications and their implications for pathology
Montoya-Novoa, I., Gardeazábal-Torbado, J. L., Alegre‐Martí, A., Fuentes‐Prior, P., & Estébanez‐Perpiñá, E. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231082 · Cited by 4
Henry, I., Foreman, R., Balachandran, L., Mortimer, E., & Asim, M. (2025) · Cancers · doi:10.3390/cancers17233755 · Cited by 4
Gandupalli, L., Bhowmik, D., Jyotishi, C., & Gupta, R. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.313 · Cited by 4
One Size Fits All in Prostate Cancer: A Story Tale Whose Time has Come and Gone
Farooqı, A. A., Bhatti, S., Nawaz, A., & Khalid, A. M. (2011) · The International Journal of Biological Markers · doi:10.5301/jbm.2011.8368 · Cited by 4
Linear mRNA amplification approach for RNAseq from limited amount of RNA
Ferreira, E. N., Molina, G. D. C., Puga, R., Nagai, M. A., Campos, A. H. J. F. M., Guimarães, G. C., Nunes, D. N., Pasqualini, R., Arap, W., Brentani, H., et al. (2015) · Gene · doi:10.1016/j.gene.2015.03.058 · Cited by 4
Metadata
- Authors
- Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Human Oncology and Pathogenesis Program,
- Bioinformatics Core,
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Sawyers, Charles L.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2010-09-07
- Volume
- 107
- Issue
- 39
- Pages
- 16759-16765
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2947883
- OpenAlex
- W2083926838
- Cited by
- 639
- References
- 27
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 22 · 2023: 33 · 2022: 25 · 2021: 26 · 2020: 43 · 2019: 33 · 2018: 36 · 2017: 43 · 2016: 63 · 2015: 48 · 2014: 64 · 2013: 65 · 2012: 53
- FWCI
- 46.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Prostate Cancer Foundation
- University of Washington
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- androgen receptor splice variants, castration-resistant prostate cancer, AR-V7, ligand-independent receptor activation, full-length androgen receptor, androgen withdrawal, antiandrogen resistance, enzalutamide, anchorage-independent growth, siRNA knockdown, prostate cancer cell lines, androgen receptor isoforms
- MeSH terms
- Amino Acid Sequence, Androgens, Animals, Castration, Disease Models, Animal, Exons, Humans, Male, Molecular Sequence Data, Prostatic Neoplasms, Receptors, Androgen, RNA, Messenger, Gene Expression Regulation, Neoplastic, Alternative Splicing, Protein Structure, Tertiary, Sequence Analysis, Protein, Cell Line, Tumor, Mice, Androgen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
